Year All20242023202220212020201920182017 Inozyme Pharma to Present at Upcoming Investor Conferences Nov 11, 2021 Inozyme Pharma Reports Third Quarter 2021 Financial Results and Provides Business Highlights Nov 09, 2021 Inozyme Pharma Announces Presentation of Data from ENPP1 Deficiency Development Program at the ASBMR 2021 Annual Meeting Oct 04, 2021 Inozyme Pharma to Present at the 2021 Cantor Virtual Global Healthcare Conference Sep 22, 2021 Inozyme Pharma Reports Q2 2021 Financial Results and Provides Business Highlights Aug 11, 2021 Inozyme Pharma to Participate in 2021 Wedbush PacGrow Healthcare Virtual Conference Aug 04, 2021 Inozyme Pharma Receives Orphan Drug Designation for INZ-701 from the European Medicines Agency for the Treatment of ABCC6 Deficiency Jul 21, 2021 Inozyme Pharma Announces Appointment of Gayle Gironda as Senior Vice President, Human Resources Jul 13, 2021 Inozyme Announces Acceptance of First European Clinical Trial Application for Phase 1/2 Clinical Trial of INZ-701 in ABCC6 Deficiency Jun 09, 2021 Inozyme Pharma Reports Q1 2021 Financial Results and Provides Business Highlights May 12, 2021
Year All20242023202220212020201920182017 Inozyme Pharma to Present at Upcoming Investor Conferences Nov 11, 2021 Inozyme Pharma Reports Third Quarter 2021 Financial Results and Provides Business Highlights Nov 09, 2021 Inozyme Pharma Announces Presentation of Data from ENPP1 Deficiency Development Program at the ASBMR 2021 Annual Meeting Oct 04, 2021 Inozyme Pharma to Present at the 2021 Cantor Virtual Global Healthcare Conference Sep 22, 2021 Inozyme Pharma Reports Q2 2021 Financial Results and Provides Business Highlights Aug 11, 2021 Inozyme Pharma to Participate in 2021 Wedbush PacGrow Healthcare Virtual Conference Aug 04, 2021 Inozyme Pharma Receives Orphan Drug Designation for INZ-701 from the European Medicines Agency for the Treatment of ABCC6 Deficiency Jul 21, 2021 Inozyme Pharma Announces Appointment of Gayle Gironda as Senior Vice President, Human Resources Jul 13, 2021 Inozyme Announces Acceptance of First European Clinical Trial Application for Phase 1/2 Clinical Trial of INZ-701 in ABCC6 Deficiency Jun 09, 2021 Inozyme Pharma Reports Q1 2021 Financial Results and Provides Business Highlights May 12, 2021
Inozyme Pharma Reports Third Quarter 2021 Financial Results and Provides Business Highlights Nov 09, 2021
Inozyme Pharma Announces Presentation of Data from ENPP1 Deficiency Development Program at the ASBMR 2021 Annual Meeting Oct 04, 2021
Inozyme Pharma Receives Orphan Drug Designation for INZ-701 from the European Medicines Agency for the Treatment of ABCC6 Deficiency Jul 21, 2021
Inozyme Pharma Announces Appointment of Gayle Gironda as Senior Vice President, Human Resources Jul 13, 2021
Inozyme Announces Acceptance of First European Clinical Trial Application for Phase 1/2 Clinical Trial of INZ-701 in ABCC6 Deficiency Jun 09, 2021